Make the best use of life in this era.
George Floyd's final words, "I can't breathe," before he died from asphyxiation after a white police officer knelt on his neck while detaining him on 25 May, are reverberating in cities across Europe.
Thousands of people in countries including the UK, France, Germany, Spain, Belgium, the Netherlands, Slovakia, Greece, Ireland, Poland, Sweden and others, have taken to the streets in anti-racism protests as a show of solidarity with protesters in the U.S., but also to echo calls for an end to racial injustice and police brutality globally.
"What's happening now is that George Floyd's death is resonating in Europe, because it's also connected to ongoing movements and activism against police violence in those societies," Jean Beaman, professor of sociology at the University of California, Santa Barbara, told CGTN Europe.
The International Council of Nurses (ICN) is again calling on governments to record the number of infections and deaths among healthcare staff, and take whatever measures are needed to protect nurses from COVID-19.
Worldwide, there is no systematic and standardised record of the number of nurses and healthcare workers (HCWs) who have contracted the disease or died from it.
But ICN’s analysis, based on data from our National Nursing Associations, official figures and media reports from a limited number of countries, indicates that more than 230,000 HCWs have contracted the disease, and more than 600 nurses have now died from the virus.
If there is a bright spot in the global response to the pandemic, it is surely New Zealand. While governments worldwide have vacillated on how to respond and ensuing cases of the virus have soared, New Zealand has set an uncompromising, science-driven example. Though the country didn’t ban travel from China until February 3 (a day after the United States) and its trajectory of new cases looked out of control in mid-March, austerity measures seemingly have brought COVID-19 to heel.
The country began mandatory quarantines for all visitors on March 15, one of the strictest policies in the world at the time, even though there were just six cases nationwide. Just 10 days later, it instituted a complete, countrywide lockdown, including a moratorium on domestic travel. The Level 4 restrictions meant grocery stores, pharmacies, hospitals, and petrol stations were the only commerce allowed; vehicle travel was restricted; and social interaction was limited to within households.
“We must fight by going hard and going early,” Prime Minister Jacinda Ardern said in a statement to the nation on March 14.
Workers clocked out on Sunday after spending 28 days at the plant making material for PPE.
(CNN)Workers at a Pennsylvania manufacturing plant got to clock out and go home for the first time in almost a month after a marathon effort to make material needed for personal protective medical equipment.
More than 40 employees volunteered to spend 28 days at the Braskem America plant in Marcus Hook, near Philadelphia, to make polypropylene -- a raw material needed to make N95 masks, medical gowns and other protective gear, CNN affiliate WPVI reported. They went home on Sunday.
A potential vaccine for COVID-19 has been developed and tested successfully in mice, researchers reported Thursday (04/02/2020).
"We'd like to get this into patients as soon as possible," said Andrea Gambotto, associate professor of surgery at the University of Pittsburgh School of Medicine and co-author of a paper announcing the vaccine in the journal EBioMedicine.
As far as reaching clinical trials, "we would like to think a month, give or take. Maybe two months. We just started the process," said co-author Louis Falo, a professor and chairman of the Department of Dermatology at the University of Pittsburgh.
The New Jersey-based healthcare giant ambitiously aims for an emergency rollout of its strongest vaccine candidate in January 2021.
Johnson & Johnson said March 31 that it had arranged a partnership with an arm of the U.S. Department of Health and Human Services to continue development on a vaccine to prevent COVID-19. Janssen Pharmaceutical Companies, a division of Johnson & Johnson, will work with the Biomedical Advanced Research and Development Authority, or BARDA, to fund and quickly test what J&J says is their leading candidate for a coronavirus vaccine.
According to Johnson & Johnson, researchers began development of possible vaccines in January, after coronavirus’s genetic sequencing became available to researchers. Janssen’s research was conducted in collaboration with Beth Israel Deaconess Medical at Harvard Medical School, and eventually yielded one lead candidate with a promising immune response and two backup candidates. J&J’s partnership with BARDA will supply the company with half of the $1 billion capital needed to expedite testing and manufacturing of the drug.
PITTSBURGH – University of Pittsburgh School of Medicine scientists today (04/02/2020) announced a potential vaccine against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic. When tested in mice, the vaccine, delivered through a fingertip-sized patch, produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus.
The paper appeared today in EBioMedicine, which is published by The Lancet, and is the first study to be published after critique from fellow scientists at outside institutions that describes a candidate vaccine for COVID-19. The researchers were able to act quickly because they had already laid the groundwork during earlier coronavirus epidemics.
Doctors at Children's Hospital Colorado hoping to save lives amid a global pandemic are calling on people who have already recovered from COVID-19 to donate their plasma, part of an experimental treatment to help patients who are still sick.
"People who have recovered from coronavirus have a ton of antibodies," said Dr. Kyle Annen, medical director at the Children's Blood Donor Center. "So what we're doing is we're taking the plasma from the people that are just recovered from coronavirus but no longer have the virus, and then transfusing it into people who currently have the virus, but haven't made enough antibodies to defeat the illness yet, in hopes that will help them to kind of get over the hump and start getting better."